Notice of Clarification to RFA-NS-18-042, "Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R21 Clinical Trial Not Allowed)"

Notice Number: NOT-AT-19-026

Key Dates
Release Date: May 7, 2019

Related Announcements
RFA-NS-18-042

Issued by
National Center for Complementary and Integrative Health (NCCIH)
National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this Notice is to clarify the “Research Objectives” section for RFA-NS-18-042, “Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R21 Clinical Trial Not Allowed)”. The below revisions are effective immediately and apply for the July 11, 2019 Application Due Date.

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Research Objectives

Currently reads:

  • Applications to identify targets for devices, such as peripheral nerve, spinal cord, or deep brain stimulators may focus on identifying electrophysiological signatures for acute or chronic pain. Validation of these targets in large animals or nonhuman primates should be considered.

Revised to read:

  • Applications to identify and validate targets for devices such as invasive or non-invasive nerve stimulators, or acupoint-based or other transcutaneous peripheral stimulations for acute or chronic pain. Applications may identify either nervous system targets or non-neural targets (e.g., connective tissues, lymphatic, or glymphatic targets) for pain. Validation of these targets in large animals or nonhuman primates should be considered.
  • Applications may propose discovery and validation of targets on any sensory systems (e.g., olfaction, vision, audition, somatosensation, interoception, etc.) for acute or chronic pain. This includes targets for pharmacological as well as non-pharmacological approaches (e.g., mind-body approaches, natural products, and devices).
  • Studies focused on the efficacy or effectiveness of a therapeutic molecule or a type of treatment, such as yoga or acupuncture, for pain are not responsive to this RFA, even if this is only part of the application.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Inna Belfer, MD, PhD
National Center for Complementary and Integrative Health (NCCIH)
Telephone: 301-435-1573
Email: inna.belfer@nih.gov

Michael L. Oshinsky, PhD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9964
Email: michael.oshinsky@nih.gov